Practical implication
Manufacturers must generate and maintain scientific, engineering, and clinical evidence demonstrating that their devices meet the Essential Principles for Safety and Performance.
The Therapeutic Goods Administration (TGA) has released guidance detailing expectations for manufacturers and sponsors of medicinal cannabis vaping devices to ensure adherence to Essential Principles of Safety and Performance. This document aims to assist sponsors in understanding the necessary evidence and industry standards required for compliance, although it does not introduce new regulatory requirements. It is critical for medical device vigilance and post-market safety monitoring.
What changed: Manufacturers and sponsors are now required to comply with established safety and performance standards for medicinal cannabis vaping devices as outlined in the TGA guidance.
Why it matters: Compliance with these standards is essential for ensuring the safety and efficacy of medicinal cannabis vaping devices, thereby enhancing post-market safety monitoring efforts.
Practical implication: Manufacturers must generate and maintain scientific, engineering, and clinical evidence demonstrating that their devices meet the Essential Principles for Safety and Performance.
View original source
Published from the Firecrawl policy change extraction pipeline.
